Covid Vaccine Race

Reasons given for not vaccinating were safety issues and low risk for infection.

A conversation with Anna Legreid Dopp, Pharm. D.

With new mask guidance comes questions and confusion, especially with the new strain of COVID-19 and those who have been vaccinated.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

Public information campaigns may potentially boost rates of vaccination.

Asymptomatic and symptomatic COVID-19 cases among health care personnel were reduced after vaccination despite surge in infected patients.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

The statement includes over 50 societies and organizations, representing millions of workers.

While a significantly reduced effectiveness was seen with 1 dose, only a small reduction was observed after 2.

Impaired resilience was found to be associated with loneliness.

The designation moves the companies' PDUFA date up to January 2022, when BNT162b2 may become the first regulated COVID-19 vaccine.

The Johnson & Johnson vaccine showed neutralizing antibody responses against variants of concern.

Before other states adopt randomly-selected payouts for COVID-19 vaccine administration, further research is needed into these lotteries’ effects on potential increases in vaccination rates.

Those taking methotrexate had lower seroconversion rates compared to controls.

A meeting between developers and federal experts was inconclusive to the necessity of a third mRNA dose for COVID-19.

The CDC announced 100 preliminary cases of Guillain-Barré syndrome following vaccine administration.

While infection risk is not eliminated, the vaccine still provided significant protection.

This serious adverse event has been linked with COVID-19 shots from AstraZeneca and Janssen.

The announcement aligns with an FDA and CDC statement against the need for booster doses.

In the second installment of an interview, members of the FlowMetric Life Sciences' leadership discuss how their technology might aid possible COVID-19 vaccine booster shots, how immunocompromised patients respond to vaccines, and other vaccines where their platform may be used.

The Sinovac developed vaccine could greatly aid in the global inoculation effort.

Two doses of the Pfizer or AstraZeneca vaccines generated high sero-neutralization against the strain.

While the efficacy of SARS-CoV-2 vaccines have been demonstrated, a lack of data is present for patients with cancer.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

Benefits were also observed among adults aged 18 to 49, with adults over 65 seeing the most benefit.

A single dose of mRNA vaccine proved 81% effective against a SARS-CoV-2 infection.

The therapy demonstrated an efficacy of 65.2% against the Delta variant.

New data suggest countries with limited vaccine supplies may not need to immediately vaccinate all members of low-risk households.

The activity was higher than what was recently observed for the South African variant.